Abstracts tagged "Outcome measures"

Abstract Number: 0644 • ACR Convergence 2024
Scoping Literature Review to Identify Candidate Domains for the SLE OMERACT Core Outcome Set
Wils Nielsen¹, Fadi Kharouf², Carolina Munoz-Grajales³, Aarabi Thayaparan⁴, Melanie Anderson⁵, Lee Simon⁶, Maya Desai⁷, Ioannis Parodis⁸, Alfred Kim⁹, Yvonne Enman¹⁰, Kathleen Bingham¹¹, Dennisse Bonilla¹¹, Julian Thumboo¹², Marta Mosca¹³, Martin Aringer¹⁴, Eric Morand¹⁵, Ian Bruce¹⁶, Vibeke Strand¹⁷ and Zahi Touma⁴, ¹University of Toronto, Markham, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³UHN/TWH, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ⁶SDG LLC, West Newton, MA, ⁷Ontario College of Art and Design University, Toronto, ON, Canada, ⁸Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ⁹Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹⁰Karolinska Institutet, Stockholm, Sweden, ¹¹University Health Network, Toronto, ON, Canada, ¹²Singapore General Hospital, Singapore, Singapore, ¹³University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ¹⁴University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ¹⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ¹⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁷Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Systemic Lupus Erythematosus (SLE) Working Group was re-established in 2018 to update the SLE Core Outcome Set (COS)…
Abstract Number: 0818 • ACR Convergence 2024
Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Lykke Oernbjerg¹, Brigitte Michelsen², Tore K. Kvien³, Simon Horskjær Rasmussen⁴, Jakub Závada⁵, Kristýna Bubová⁶, Bente Glintborg⁷, Anne Gitte Loft⁸, Ana Maria Rodrigues⁹, Maria Jose Santos¹⁰, Adrian Ciurea¹¹, Michael Nissen¹², Laura Kuusalo¹³, Jarno Rutanen¹⁴, Ziga Rotar¹⁵, Katja Perdan-Pikmajer¹⁵, Bjorn Gudbjornsson¹⁶, Olafur Palsson¹⁷, Daniela DiGuiseppe¹⁸, Mikkel Ostergaard¹⁹ and Merete Hetland²⁰, ¹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴Rigshospitalet Glostrup, Glostrup, Denmark, ⁵Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁶Institute of Rheumatology and Charles University, Prague, Czech Republic, ⁷DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ⁸Aarhus University Hospital and Aarhus University, Horsens, Denmark, ⁹Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, ¹⁰Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ¹¹University Hospital Zurich, Zürich, Switzerland, ¹²Geneva University Hospital, Geneva, Switzerland, ¹³University of Turku and Turku University Hospital, Turku, Finland, ¹⁴Tampere University Hospital, Tampere, Finland, ¹⁵University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁶Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁷University of Iceland and Skåne University Hospital, Reykjavik, Iceland, ¹⁸Karolinska Institutet, Stockholm, ¹⁹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ²⁰Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: While the Axial Spondyloarthritis Disease Activity Score based on C-reactive protein (ASDAS) is recommended for assessment of disease activity in patients with axial spondyloarthritis…
Abstract Number: 1137 • ACR Convergence 2024
Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)
Kristina Callis Duffin¹, Christopher E. M. Griffiths², Matthias Hoffmann³, Andrew Blauvelt⁴, Eugene Balagula⁵, Andrew Napoli⁵, Ying-Ming Jou⁵, Rachel Dyme⁵, Virginia Hala⁵, andreas pinter⁶ and Mark Lebwohl⁷, ¹University of Utah, Salt Lake City, ²Dermatology Centre, University of Manchester, Manchester, and King’s College Hospital and King’s College London, London, United Kingdom, ³Private Practice, Witten, Germany, ⁴Oregon Medical Research Center, Portland, OR, ⁵Bristol Myers Squibb, Princeton, ⁶University Hospital of the Goethe University, Frankfurt am Main, Frankfurt, Germany, ⁷Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in the US, EU, and other countries for treatment of adults with…
Abstract Number: 1498 • ACR Convergence 2024
Gender Disparities in Clinical Manifestations and Outcomes of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mazen Allouni¹, Muhammad Shamim², Krista Topalsky³ and Omer Pamuk⁴, ¹Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, ²University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ³University Hospitals/ Case Western Reserve University, Shaker Heights, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: The clinical manifestations and outcomes of systemic lupus erythematosus (SLE) reveal notable gender differences, which may impact treatment strategies and patient outcomes. This meta-analysis…
Abstract Number: 1882 • ACR Convergence 2024
30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database
Shobhit Piplani¹, Priyanshu Jain², Vladimir Jelic³, Clement Tagoe⁴ and Beverly Johnson⁵, ¹Jacobi Medical Center/North Central Bronx Albert Einstein College of Medicine NYC Health and Hospitals, Bronx, NY, ²Jawaharlal Nehru Medical College, Belgaum, Karnataka, India, Bronx, NY, ³Jacobi Medical Center/North Central Bronx, Bronx, NY, ⁴Albert Einstein College of Medicine, FRESH MEADOWS, NY, ⁵Albert Einstein College of Medicine, New York, NY
Background/Purpose: Rheumatoid Arthirits (RA) is associated with heightened morbidity, diminished quality of life, and increased healthcare expenses. This research aims to bridge this gap by…
Abstract Number: 2218 • ACR Convergence 2024
Association Between Frailty and Peri-Operative Inpatient Adverse Outcomes Among Patients with and Without Rheumatoid Arthritis
Ali Yazdanyar¹, Joshua Baker², Katherine Wysham³ and Michael Ward⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴NIH, Bethesda, MD
Background/Purpose: Frailty is a state reflecting a reduced physiologic reserve. There is accumulating literature on the prevalence and clinical significance of frailty in Rheumatoid Arthritis…
Abstract Number: 2466 • ACR Convergence 2024
Ranked Composite Important Difference (RCID) Scores in Patients with Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease
Francesco Del Galdo¹, Lesley-Anne Bissell², Rozeta Simonovska³ and Margarida Alves⁴, ¹University of Leeds, Leeds, United Kingdom, ²Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁴Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany
Background/Purpose: The ACR Composite Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) was developed to measure the probability of improvement in response to treatment in…
Abstract Number: 0266 • ACR Convergence 2024
Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol
Dansoa Tabi-Amponsah¹, Lisa Stamp², Anne Horne³, Jill Drake⁴, Sarah Stewart⁵, Gregory Gamble³, Keith Petrie¹ and Nicola Dalbeth³, ¹The University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Auckland University of Technology, Auckland, New Zealand
Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…
Abstract Number: 0541 • ACR Convergence 2024
Measurement Properties of Disease Activity Instruments in Peripheral Spondyloarthritis. an Analysis in the CRESPA Trial
Clementina López Medina¹, Anna Molto², Dafne Capelusnik³, Philippe Carron⁴, Casper Webers⁵, Filip Van den Bosch⁶, Annelies Boonen⁷ and Sofia Ramiro⁸, ¹Reina Sofia University Hospital, Cordoba, Spain, ²Groupe Hospitalier Cochin, AP-HP, Paris, France, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴UZ Gent, Gent, Belgium, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center; Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands, ⁸Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Understanding the best-performing disease activity measure and response criterion in peripheral spondyloarthritis (pSpA) is crucial for the development of future meaningful clinical studies. The…
Abstract Number: 0656 • ACR Convergence 2024
Lupus Myocarditis: Clinical Characteristics, Cardiac Magnetic Resonance Imaging Findings and Outcomes
María del Carmen Zamora-Medina¹, Erik Cimé-Aké², Emilio G. Lazarini², Wallace Rafael A. Muñoz-Castañeda³ and Hilda Fragoso-Loyo², ¹Instituto Nacional de Perinatología "Isidro Espinoza de los Reyes". Rheumatology Department, Mexico City, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department, Mexico City, Mexico, ³Hospital Medica Sur. Rheumatology Department, Mexico City, Distrito Federal, Mexico
Background/Purpose: Limited information about lupus myocarditis (LM) comes from small case series. The aim of our study is to describe and compare clinical characteristics, cardiac…
Abstract Number: 0847 • ACR Convergence 2024
Sex and Race-Specific Distributions in Medial Fixed Joint Space Width in Healthy Knees from Three Longitudinal Cohorts
Kent Kwoh¹, Rongrong Tang², Erin Ashbeck³, Edward Bedrick⁴, Yvonne Golightly⁵, Amanda Nelson⁶, Tuhina Neogi⁷, Yong Ge⁸, Zong-Ming Li², Jean Liew⁷, Xiaoxiao Sun⁹, Justin Crawmer¹⁰ and Jeffery Duryea¹¹, ¹University of Arizona, Tucson, AZ, ²University of Arizona Arthritis Center, University of Arizona College of Medicine - Tucson, Tucson, AZ, ³University of Arizona Mel and Enid Zuckerman College of Public Health, Tucson, AZ, ⁴Department of Epidemiology andBiostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁷Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁸Department of Information Sciences, Eller College of Manangement, University of Arizona, Tucson, AZ, ⁹Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ¹⁰BWH, Boston, MA, ¹¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Quantitative radiographic joint space width (JSW) is often used as ameasure of structural outcomes in randomized controlled trials of knee OA (KOA). How JSW…
Abstract Number: 1148 • ACR Convergence 2024
Simplified Cutaneous Dermatomyositis Disease Area and Severity Index Activity Scores for Cutaneous Dermatomyositis
Nantakarn Pongtarakulpanit¹, Tanya Chandra¹, shiri keret², Eugenia Gkiaouraki³, Vladimir Liarski¹, Dana Ascherman³, Siamak Mogahadam¹, Chester Oddis¹ and Rohit Aggarwal⁴, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, ³Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA
Background/Purpose: The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) is a clinician-scored instrument that measures activity and damage in the skin of Dermatomyositis (DM)…
Abstract Number: 1502 • ACR Convergence 2024
The Systemic Lupus International Collaborating Clinics (SLICC) Frailty Index (SLICC-FI) Predicts Hospitalizations. Data from the Almenara Lupus Cohort
Manuel Ugarte-Gil¹, RV, Gamboa-Cardenas², Victor Pimentel-Quiroz³, Cristina Reategui⁴, Claudia Elera Fitzcarrald⁵, Cesar Pastor-Asurza⁶, Zoila Rodriguez-Bellido⁶, Risto Perich-Campos⁶ and Graciela Alarcon⁷, ¹Universidad Cientifica del Sur, Lima, Lima, Peru, ²Universidad Científica del Sur, Lima, Lima, Peru, ³Universidad Científica del Sur/Hospital Nacional Guillermo Almenara Irigoyen, Magdalena del Mar, Peru, ⁴Servicio de Reumatología. Hospital Nacional Guillermo Almenara Irigoyen, EsSalud/Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Lima, Peru, ⁵Hospital Nacional Guillermo Almenara Irigoyen/Universidad San Ignacio de Loyola, Lima, Peru, ⁶Hospital Nacional Guillermo Almenara Irigoyen, Lima, Lima, Peru, ⁷The University of Alabama at Birmingham, Oakland, CA
Background/Purpose: Frailty, measured with the SLICC-FI, has been reported as a predictor of damage in several cohorts. The aim of this study is to evaluate…
Abstract Number: 1934 • ACR Convergence 2024
Knee Symptom Phenotyping Incorporating Pain and Function: A Multiple-Trajectory Modeling-Based Study Using Data from the Osteoarthritis Initiative (OAI)
Yong Ge¹, Thang Doung², Shen Liu³, Xiaoxiao Sun⁴, Tuhina Neogi⁵, Amanda Nelson⁶, Jeffery Duryea⁷ and Kent Kwoh⁸, ¹Department of Information Sciences, Eller College of Manangement, University of Arizona, Tucson, AZ, ²Department of Computer Science, University of Arizona College of Science, Tucson, AZ, ³Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ⁴Department of Biostatistics, Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, ⁵Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁶University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁷Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁸University of Arizona, Tucson, AZ
Background/Purpose: Knee pain is the most common presenting symptom of knee OA, and functional limitations are a common sequelae. Understanding the various patterns of pain…
Abstract Number: 2245 • ACR Convergence 2024
Clinical Efficacy and Molecular Cardiovascular Changes of Baricitinib in Biologic-naïve Patients with Rheumatoid Arthritis. Direct Comparative Analysis with TNF Inhibitors and Conventional DMARDs
Chary Lopez-Pedrera¹, Laura Muñoz-Barrera², Rafaela Ortega-Castro³, Sagrario Corrales², Jerusalén Calvo⁴, Concepción Aranda-Valera⁵, María Lourdes Ladehesa-Pineda¹, Pilar Font², Ismael Sánchez Pareja², Elena Moreno-Caño⁵, María Carmen Ábalos-Aguilera⁶, Christian Merlo-Ruiz⁶, Mª Angeles Aguirre-Zamorano⁷, Tomás Cerdó², Nuria Barbarroja², Carlos Perez-Sanchez² and Alejandro Escudero-Contreras², ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain
Background/Purpose: The main objective of this study was to conduct extensive clinical and molecular analyses to accurately characterize the specific effects of Baricitinib (4 mg/day)…

« Previous Page
1
…
7
8
9
10
11
…
49
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].